Physician profile
Crystal Bernstein
NPI 1326019167
$6,316.43
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2021: $67.32 · 2022: $194 · 2023: $593 · 2024: $5,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,750 · Food and Beverage: $972 · Travel and Lodging: $183 · Education: $32.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,750.00 |
| Food and Beverage | $971.82 |
| Travel and Lodging | $182.69 |
| Education | $32.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $4,932.69 | 2024 | Omvoh |
| Abbvie INC. | $421.08 | 2019-2024 | Rinvoq, Skyrizi, Creon |
| Pfizer INC. | $365.83 | 2022-2024 | |
| Celgene Corporation | $267.86 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $90.52 | 2022-2023 | Stelara |
| Aimmune Therapeutics, INC. | $56.75 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.33 | 2023-2024 | Xifaxan, Plenvu |
| Genzyme Corporation | $26.27 | 2024 | |
| Madrigal Pharmaceuticals | $24.57 | 2024 | Resmetirom |
| Phathom Pharmaceuticals, INC. | $19.24 | 2024 | Voquezna |
| Celltrion USA INC. | $17.26 | 2023 | Yuflyma |
| Ferring Pharmaceuticals INC. | $16.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.35 | 2023 | Entyvio |
| Intercept Pharmaceuticals, INC. | $15.29 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.